NCT02282605View on ClinicalTrials.gov

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Staphylococcus Aureus Infection

Interventions

DRUG

XF-73 nasal gel

DRUG

Placebo nasal gel

OTHER

Chlorhexidine gluconate 2% topical cloths

Trial Locations (1)

SE11 1YR

Quintiles Drug Research Unit, London

Sponsors

Lead Sponsor

Destiny Pharma Plc

All Listed Sponsors

lead

Destiny Pharma Plc

INDUSTRY